Treatment with immune checkpoint inhibitors after EGFR-TKIs in EGFR-mutated lung cancer.
Treatment with immune checkpoint inhibitors after EGFR-TKIs in EGFR-mutated lung cancer.
复制标题
DOI：
10.1111/1759-7714.14267
复制
发表时间：
2022-03
期刊：
影响因子：
2.9
通讯作者：
Maemondo M
中科院分区：
文献类型：
--
作者：
Ito T;Nagashima H;Akiyama M;Utsumi Y;Sato H;Chiba S;Sugai M;Ube K;Mori Y;Watanabe K;Fukuhara T;Maemondo M
表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）已成为EGFR突变型非小细胞肺癌（NSCLC）治疗的金标准。免疫检查点抑制剂（ICI）已被开发用于治疗几种恶性肿瘤，包括肺癌。然而，已知ICI在EGFR突变NSCLC中的疗效较差。我们收集了2015年12月至2020年3月在三家机构接受EGFR-TKI后接受ICI单药治疗的EGFR突变NSCLC患者的数据，并回顾性分析了患者特征与ICI疗效之间的相关性。本研究共纳入25例患者。我们将反应者定义为接受90天或更长时间ICI治疗的患者。比较应答者和非应答者之间的特征，在应答者中观察到比非应答者更多的具有L 858 R EGFR突变的肿瘤（L 858 R：分别为66.7%和25.0%，p < 0.05）。ICI治疗前T790 M耐药突变发生率无差异。应答者的PD-L1阳性率略高，但无统计学显著性（分别为22.2%和12.5%）。ICI应答者的EGFR‐TKI预治疗中位持续时间短于非应答者（分别为13.3和19.9个月）。L 858 R肿瘤患者的生存期显著长于外显子19缺失患者（HR：0.35，95% CI：0.13-0.93，p = 0.026）。ICI治疗在L 858 R突变肿瘤患者中往往具有更好的疗效。本研究表明，L 858 R突变NSCLC患者是EGFR‐TKI治疗后ICI治疗的候选者。观察ICI对部分EGFR突变NSCLC患者的疗效。ICI治疗具有L 858 R突变的肿瘤比外显子19缺失的肿瘤获得更好的反应。本研究表明，L 858 R突变NSCLC患者是EGFR‐TKI治疗后ICI治疗的候选者。
Epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) have become the gold standard for EGFR‐mutated non‐small cell lung cancer (NSCLC) treatment. Immune checkpoint inhibitors (ICIs) have been developed for the treatment of several malignancies, including lung cancer. However, it is known that ICIs have poorer efficacy in EGFR‐mutated NSCLC. We collected data for patients with EGFR‐mutated NSCLC receiving monotherapy with ICIs after EGFR‐TKIs between December 2015 and March 2020 in three institutions, and retrospectively analyzed the association between patient characteristics and efficacy of ICIs. A total of 25 patients were included in this study. We defined responders as patients undergoing 90 days or longer of ICI treatment. Comparing characteristics between responders and non‐responders, more tumors with L858R EGFR mutation were observed in responders than in non‐responders (L858R: 66.7% and 25.0%, respectively, p < 0.05). There was no difference in incidence of T790M resistance mutation before ICI treatment. The PD‐L1 positive rate was slightly higher in responders but not statistically significant (22.2% and 12.5%, respectively). Median duration of EGFR‐TKI pretreatment was shorter in ICI responders compared with nonresponders (13.3 and 19.9 months, respectively). The survival of patients with L858R tumors was significantly longer than that of patients with exon 19 deletion (HR: 0.35, 95% CI: 0.13–0.93, p = 0.026). ICI treatment tends to have better efficacy in patients with L858R‐mutated tumors. This study suggests that patients with L858R‐mutated NSCLC are candidates for ICI treatment after EGFR‐TKI treatment. Efficacy of ICI in a part of patients with EGFR‐mutated NSCLC was observed. ICI treatments in tumors with L858R mutation achieved a better response than exon 19 deletion. This study suggests that patients with L858R‐mutated NSCLC are candidates for ICI treatment after EGFR‐TKI treatment.
登录
查看更多内容
影响因子：
16.6
作者：
Shin HT;Choi YL;Yun JW;Kim NKD;Kim SY;Jeon HJ;Nam JY;Lee C;Ryu D;Kim SC;Park K;Lee E;Bae JS;Son DS;Joung JG;Lee J;Kim ST;Ahn MJ;Lee SH;Ahn JS;Lee WY;Oh BY;Park YH;Lee JE;Lee KH;Kim HC;Kim KM;Im YH;Park K;Park PJ;Park WY
通讯作者：
Park WY
影响因子：
158.5
作者：
Lynch, TJ;Bell, DW;Haber, DA
通讯作者：
Haber, DA
DOI：
10.1016/j.jtho.2018.03.035
发表时间：
2018-08
期刊：
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
影响因子：
--
作者：
Lisberg A;Cummings A;Goldman JW;Bornazyan K;Reese N;Wang T;Coluzzi P;Ledezma B;Mendenhall M;Hunt J;Wolf B;Jones B;Madrigal J;Horton J;Spiegel M;Carroll J;Gukasyan J;Williams T;Sauer L;Wells C;Hardy A;Linares P;Lim C;Ma L;Adame C;Garon EB
通讯作者：
Garon EB
DOI：
10.1158/1078-0432.ccr-15-3101
发表时间：
2016-09-15
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Gainor JF;Shaw AT;Sequist LV;Fu X;Azzoli CG;Piotrowska Z;Huynh TG;Zhao L;Fulton L;Schultz KR;Howe E;Farago AF;Sullivan RJ;Stone JR;Digumarthy S;Moran T;Hata AN;Yagi Y;Yeap BY;Engelman JA;Mino-Kenudson M
通讯作者：
Mino-Kenudson M
影响因子：
45.3
作者：
Masters, Gregory A.;Temin, Sarah;Johnson, David H.
通讯作者：
Johnson, David H.